Classical Chemotherapy of metastatic melanoma;Klassische Chemotherapie des metastasierenden melanoms

H+G Zeitschrift fur Hautkrankheiten

Volumn 75, Issue 9, 2000, Pages 553-558

  Becker, J C ^a   Kampgen E ^a   Brocker E B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Metastatic melanoma; Monochemotherpy; Polychemotherapy; Uveal melanoma

Indexed keywords

EID: 0141607415     PISSN: 03010481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chowdhury, S., M. M. Vaughan, M. E. Gore (1999): New approaches to the systemic treatment of melanoma. Cancer Treat. Rev. 25, 259-70.
2. Retsas, S. (1998): Adjuvant therapy of melanoma. Lancet 352, 737-8.
3. Eton, O., S. S. Legha, T. E. Moon, A. C. Buzaid, N. E. Papadopoulos, C. Plager, A. M. Burgess, A. Y. Bedikian, S. Ring, Q. Dong et al. (1998): Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16, 1103-11.
4. Mooy, CM, de J. P. (1996). Prognostic parameters in uveal melanoma: a review. Surv. Ophthalmol. 41, 215-28.
5. Chapman, P. B., L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff et al. (1999): Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 17, 2745-51.
6. Ahmann, D. L., E. T. Creagan, R. G. Hahn, J. H. Edmonson, H. F. Bisel, D. J. Schaid (1989). Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63, 224-7.
7. Ceci, G., M. Bella, M. Melissari, M. Gabrielli, P. Bocchi, G. Cocconi (1988): Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 61, 1988-91.
8. O'Reilly, S. M., E. S. Newlands, M. G. Glaser, M. Brampton, J. M. Rice-Edwards, R. D. Illingworth, P. G. Richards, C. Kennard, I. R. Colquhoun, P. Lewis (1993): Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 29, 940-2.
9. Brock, C. S., E. S. Newlands, S. R. Wedge, M. Bower, H. Evans, I. Colquhoun, M. Roddie, M. Glaser, M. H. Brampton, G. J. Rustin (1998): Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 58, 4363-7.
10. Sampson, J. H., G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, H. S. Friedman (1999): Treatment of neoplastic meningitis with intrathecal temozolomide. Clin. Cancer Res. 5, 1183-8.
11. Middleton, M. R., J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates et al. (2000): Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma. J. Clin. Oncol. 18, 158
12. Khayat, D., B. Giroux, J. Berille, V. Cour, B. Gerard, M. Sarkany, P. Bertrand, J. P. Bizzari (1994): Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest. 12, 414-20.
13. Jacquillat, C., D. Khayat, P. Banzet, M. Weil, P Fumoleau, M. F. Avril, M. Namer, J. Bonneterre, P. Kerbrat, J. J. Bonerandi (1990): Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66, 1873-8.
14. Nathan, F. E., D. Berd, T Sato, M. J. Mastrangelo (2000): Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer 88, 79-87.
15. Steffens, T. A., D. F. Bajorin, P. B Chapman, D. R. Lovett, B. V. Cody-Johnson, M. A. Templeton, R. T. Heelan, G. Y. Wong, C. S. Portlock, H. F. Oettgen (1991): A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer 68, 1230-7.
16. Del Prete, S. A., L. H. Maurer, J. O'Donnell, R. J. Forcier, P. LeMarbre (1984): Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma Cancer Treat. Rep. 68, 1403-5.
17. Creagan, E. T., V. J. Suman, R. J. Dalton, H. C. Pitot, H. J. Long, M. H. Veeder, A. M. Vukov, K. M. Rowland, J. E Krook, J C. Michalak (1999): Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin Oncol. 17, 1884
18. Meisenberg, B (1996): High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Bone Marrow Transplant 17, 903-6.
19. Cassel, W. A., Z. L Olkowski, D. R. Murray (1999): Immunotherapy in malignant melanoma. J. Clin. Oncol. 17, 1958
20. Legha, S. S., S. Ring, O Eton, A Bedikian, A. C. Buzaid, C Plager, N. Papadopoulos (1998): Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J.Clin.Oncol. 16, 1752-9.
21. Bedikian, A. Y., S. S. Legha, G Mavligit, C. H. Carrasco, S Khorana, C. Plager. N. Papadopoulos, R. S. Benjamin (1995): Treatment of uveal melanoma metastatic to the liver a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76, 1665-70.
22. Leyvraz, S., V Spataro, J. Bauer, S. Pampaliona, R. Salmon, T. Dorval, R. Meuli, M. Gillet, F. Lejeune, L. Zografos L (1997). Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J. Clin. Oncol. 15, 2589-95.
23. Leyvraz, S., V. Spataro, J. Bauer, S. Pampallona, R. Salmon, T. Dorval, R. Meuli, M. Gillet, F. Lejeune, L. Zografos (1997): Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J. Clin Oncol. 15, 2589-95.
24. Pyrhonen, S. (1998): The treatment of metastatic uveal melanoma. Eur. J Cancer 34 Suppl 3, S27-S30
25. Nathan, F. E., D. Berd, T. Sato, J. A. Shield, C L. Shields (1997): De Potter P, Mastrangelo MJ. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J. Exp. Clin. Cancer Res. 16, 201-8.
26. Gerard, B , S Aamdal, S. M. Lee, S. Leyvraz, C. Lucas, M. D'incalci, J. P. Bizzan (1993): Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur. J. Cancer 29A, 711-9.
27. Terheyden, P. E. Kämpgen, T. M. Rünger, E B. Bröcker, J. C Becker (1998): Immunochemotherapy of metastatic uveal melanoma wtth interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature. Hautarzt 49, 770-3.